NASDAQ:LQDA - Nasdaq - US53635D2027 - Common Stock - Currency: USD
16.115
-0.39 (-2.33%)
The current stock price of LQDA is 16.115 USD. In the past month the price increased by 11.91%. In the past year, price increased by 12.53%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 136 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
LIQUIDIA CORP
419 Davis Drive, Suite 100
Morrisville NORTH CAROLINA 27560 US
CEO: Neal Fowler
Employees: 145
Company Website: https://www.liquidia.com/
Investor Relations: http://www.liquidia.com/investors/overview
Phone: 19193284400
The current stock price of LQDA is 16.115 USD. The price decreased by -2.33% in the last trading session.
The exchange symbol of LIQUIDIA CORP is LQDA and it is listed on the Nasdaq exchange.
LQDA stock is listed on the Nasdaq exchange.
16 analysts have analysed LQDA and the average price target is 25.84 USD. This implies a price increase of 60.35% is expected in the next year compared to the current price of 16.115. Check the LIQUIDIA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LIQUIDIA CORP (LQDA) has a market capitalization of 1.36B USD. This makes LQDA a Small Cap stock.
LIQUIDIA CORP (LQDA) currently has 145 employees.
LIQUIDIA CORP (LQDA) has a support level at 16.11. Check the full technical report for a detailed analysis of LQDA support and resistance levels.
The Revenue of LIQUIDIA CORP (LQDA) is expected to decline by -10.25% in the next year. Check the estimates tab for more information on the LQDA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LQDA does not pay a dividend.
LIQUIDIA CORP (LQDA) will report earnings on 2025-03-13, after the market close.
LIQUIDIA CORP (LQDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.63).
The outstanding short interest for LIQUIDIA CORP (LQDA) is 18.78% of its float. Check the ownership tab for more information on the LQDA short interest.
ChartMill assigns a technical rating of 9 / 10 to LQDA. When comparing the yearly performance of all stocks, LQDA is one of the better performing stocks in the market, outperforming 90.87% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to LQDA. LQDA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months LQDA reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS decreased by -87.36% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -47.24% | ||
ROE | -108.1% | ||
Debt/Equity | 0.9 |
ChartMill assigns a Buy % Consensus number of 85% to LQDA. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -32.6% and a revenue growth -10.25% for LQDA